ENLV (Enlivex Therapeutics Ltd.) Short-Term Debt to Capital
Enlivex Therapeutics (ENLV) is based on Allocetra platform patents, creating a significant technological barrier, although R&D expenses are weighing on its market capitalization. The business relies on the development of sepsis therapy, where low demand elasticity guarantees high margins and stable FCF. This price chart illustrates the trend of the indicator, which currently stands at 0.00. However, local conflicts in the Middle East are complicating the transportation of biomaterials and laboratory operations.
Analytical breakdowns for Enlivex Therapeutics
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Enlivex Therapeutics|ENLV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Enlivex Therapeutics|ENLV - Aggregate Debt Obligations|Debts to Book Capitalization Enlivex Therapeutics Ltd|ENLV - Long-Term Debt Volume|Company Short-Term Debt Enlivex Therapeutics|Quick Liquidity enlivex.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Enlivex Therapeutics Ltd.
The analysis of Enlivex Therapeutics (ENLV) resilience to market shocks relies on the support of funds that trust the Allocetra platform within the field of intensive care. GURU.Markets tools assess the share of liabilities maturing within one year relative to equity through the dynamics of short-term liabilities to own funds, allowing investors to identify critical debt peaks by comparing current values with the company's historical trend.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|KalVista Pharmaceuticals Inc - Short-Term Debt to Capital|Current Liabilities to Capital Septerna Pharma|Pieris Pharmaceuticals (PVLA) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio SVRA|Short-Term Debt to Equity Rigel Pharmaceuticals, Inc.|Short-Term Debt to Equity ANAB|Short-Term Debt to Capital ATXS|Short-Term Debt to Capital Coefficient enGene Corp|RAPT Therapeutics - Short-Term Debt to Equity Ratio|Aerovate Therapeutics, Inc. - Short-Term Debt to Equity|Aclaris Therapeutics, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital Kyverna Therapeutics Inc.|TLSA (Tiziana Life Sciences PLC) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio CABA|Short-Term Debt to Equity Ratio VTYX|THTX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio AVTX (Avalo Therapeutics)|Short-Term Loans to Capital Ratio ELDN|Short-Term Debt to Capital AGEN (Agenus Inc)|Ratio of Short-Term Indebtedness to Capital CLYM|Zura Bio - Short-Term Debt to Capital|Current Liabilities to Capital atyrpharma.com|adagene.com (ADAG) - Short-Term Debt to Equity|Ikena Oncology - Ratio of Short-Term Indebtedness to Capital|STTK (Shattuck Labs Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Equillium Bio|Short-Term Debt to Equity Connect Biopharma (CNTB)|IMUX: Current Liabilities to Equity|Short-Term Debt to Capital ATRA (Atara Bio)|InflaRx NV (IFRX) - Current Liabilities to Capital|XFOR: Short-Term Debt to Equity Ratio|ACET - Short-Term Debt to Capital|CELU (celularity.com) - Short-Term Debt to Equity Ratio|INMB: Short-Term Loans to Capital Ratio|BRNS (Barinthus Biotherapeutics plc) - Short-Term Debt to Capital|Kezar Life Sciences Inc. (KZR) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital SABS|Short-Term Debt to Equity Ratio Akari Therapeutics, Plc AKTX|Short-Term Debt to Equity Q32 Bio QTTB|Short-Term Debt to Capital Coefficient geovax.com (GOVX)|Edesa Biotech - Short-Term Debt to Capital|Current Liabilities to Capital iBio Inc|carismatx.com (CARM) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio XTLB|Short-Term Debt to Equity Bolt Biotherapeutics Inc.|Short-Term Debt to Equity HCWB|Short-Term Debt to Equity Ratio APVO (Aptevo Therapeutics)|Short-Term Debt to Equity AIM (aimimmuno.com)|Short-Term Debt to Equity Aditxt, Inc. ADTX|GRI (GRI Bio Corporation) - Current Liabilities to Equity|XORTX Therapeutics Inc. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital HIND (reshapelifesciences.com)|REVB: Short-Term Debt to Capital|Indaptus Therapeutics Inc (INDP) - Short-Term Debt to Capital|Short-Term Debt to Equity Scinai|CALI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Affimed (AFMD)|Short-Term Debt to Equity Ratio allakos.com ALLK|Short-Term Debt to Capital HOOK (HOOKIPA Pharma)|Short-Term Debt to Capital IGM Biosciences Inc. IGMS|ITOS: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OCEA (Ocean Biomedical Corp)|TCBP: Short-Term Debt to Capital|THRD - Short-Term Debt to Capital Coefficient